Essential hypertension
Conditions
Interventions
Control group:Hydrochlorothiazide, telmisartan placebo, and rosuvastatin placebo
Telmisartan group:Hydrochlorothiazide, telmisartan, and rosuvastatin placebo
Rosuvastatin group:Hydrochlorothiazide, rosuvastatin, and telmisartan placebo
Combination group:Hydrochlorothiazide, telmisartan, and rosuvastatin
Sponsors
Institute of Basic Medicine, Shandong Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria: Essential hypertension patients aged 60 years and older who were new diagnosed and/or in process of antihypertensive treatment.
Exclusion criteria
Exclusion criteria: Secondary hypertension, diabetes mellitus, dementia; stroke; myocardial infarction; heart failure; renal failure and dialysis treatment; liver disease; definite hypersensitivity or contraindication to the study medications; unwillingness to provide informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in blood pressure;Target organ damage including hear, brain, and renal damage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in blood lipids;Parameters of artery stiffness and chronic inflammation; | — |
Countries
China
Contacts
Public ContactZhendong Liu
Institute of Basic Medicine, Shandong Academy
Outcome results
None listed